1. Saylor D, Steiner TJ. The global burden of headache. Semin Neurol. 2018;38(2):182–190. doi: 10.1055/s-0038-1646946 [PubMed] [CrossRef] [Google Scholar]
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine— current understanding and treatment. N Engl J Med. 2003;46(4):257–270. [PubMed] [Google Scholar]
3. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008;28(8):877–886. doi: 10.1111/j.1468-2982.2008.01578.x [PubMed] [CrossRef] [Google Scholar]
4. Ahn AH. On the temporal relationship between throbbing migraine pain and arterial pulse. Headache. 2010;50(9):1507–1510. doi: 10.1111/j.1526-4610.2010.01765.x [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997;37(Suppl 1):S15–25. [PubMed] [Google Scholar]
6. Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010;50(8):1353–1361. doi: 10.1111/j.1526-4610.2010.01662.x [PubMed] [CrossRef] [Google Scholar]
7. Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013;27(5):385–394. doi: 10.1007/s40263-013-0061-2 [PubMed] [CrossRef] [Google Scholar]
8. Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache. 2013;53(Suppl 2):S43–S53. doi: 10.1111/head.12184 [PubMed] [CrossRef] [Google Scholar]
9. Saper JR, Silberstein SD. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006;46(Suppl 4):S171–S181. doi: 10.1111/j.1526-4610.2006.00601.x [PubMed] [CrossRef] [Google Scholar]
10. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology and efficacy. Headache. 2003;43:144–166. doi: 10.1046/j.1526-4610.2003.03034.x [PubMed] [CrossRef] [Google Scholar]
11. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36(7):995–997. doi: 10.1212/WNL.36.7.995 [PubMed] [CrossRef] [Google Scholar]
12. Scherl ER, Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache. 1995;35(5):256–259. doi: 10.1111/j.1526-4610.1995.hed3505256.x [PubMed] [CrossRef] [Google Scholar]
13. Charles JA, Von Dohln P. Outpatient home-based continuous intravenous dihydroergotamine therapy for intractable migraine. Headache. 2010;50:852–860. doi: 10.1111/j.1526-4610.2010.01622.x [PubMed] [CrossRef] [Google Scholar]
14. Orr SL, Friedman BW, Christie S, et al. Management of adults with acute migraine in the emergency department: the American headache society evidence assessment of parenteral pharmacotherapies. Headache. 2016;56:911–940. doi: 10.1111/head.12835 [PubMed] [CrossRef] [Google Scholar]
15. Silberstein SD, Silberstein JR. Chronic daily headache: long term prognosis following inpatient treatment with repetitive IV DHE. Headache. 1992;32(9):439–445. doi: 10.1111/j.1526-4610.1992.hed3209439.x [PubMed] [CrossRef] [Google Scholar]
16. Marmura MJ, Goldberg SW. Inpatient management of migraine. Dep Neurol Fac Paper. 2015;Paper:101. [Google Scholar]
17. Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827–1832. doi: 10.1212/WNL.0b013e3182377dbb [PubMed] [CrossRef] [Google Scholar]
18. Tso AR, Patniyot IR, Gelfand AA, Goadsby PJ. Increase rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment. Neurology. 2017;89:279–283. doi: 10.1212/WNL.0000000000004108 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. Berard A, Kori S. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Headache. 2012;52(7):1085–1093. doi: 10.1111/j.1526-4610.2012.02172.x [PubMed] [CrossRef] [Google Scholar]
20. Silberstein SD. Headaches and women: treatment if the pregnant and lactating migraineur. Headache. 1993;33:533–540. doi: 10.1111/j.1526-4610.1993.hed3310533.x [PubMed] [CrossRef] [Google Scholar]
21. Burch R. Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review. Headache. 2019;60:1–17. [PubMed] [Google Scholar]
22. O’Brien HL, Kabbouche MA, Kacperski J, et al. Treatment of pediatric migraine. Curr Treat Opt Neurol. 2015;17(1):1–17. doi: 10.1007/s11940-014-0326-1 [PubMed] [CrossRef] [Google Scholar]
23. Connelly M, Sekhon S, Stephens D, et al. Enhancing outpatient dihydroergotamine infusion with interdisciplinary care to treat refractory pediatric migraine: preliminary outcomes from the comprehensive aggressive migraine protocol (“CAMP”). Headache. 2019;60:1–9. [PubMed] [Google Scholar]
24. Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in child and adolescents. Headache. 2009;49(1):106–109. doi: 10.1111/j.1526-4610.2008.01293.x [PubMed] [CrossRef] [Google Scholar]
25. Nelson GR, Bale JF, Kerr LM. Outcome and cost of inpatient hospitalization for intravenous dihydroergotamine treatment of refractory pediatric headache. Pediatr Neurol. 2017;66:76–81. doi: 10.1016/j.pediatrneurol.2016.09.009 [PubMed] [CrossRef] [Google Scholar]
26. Patniyot IR, Gelfand AA. Acute treatment therapies for pediatric migraine: A qualitative systematic review. Headache. 2016;56(1):49–70. doi: 10.1111/head.12746 [PubMed] [CrossRef] [Google Scholar]
27. Horbach T, Wolf H, Michaelis HC, et al. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Thromb Hemost. 1996;75(2):246–250. doi: 10.1055/s-0038-1650253 [PubMed] [CrossRef] [Google Scholar]
28. Labruijere S, Chan KY, de Vries R, et al. Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein. Cephalalgia. 2015;35(2):182–189. doi: 10.1177/0333102414544977 [PubMed] [CrossRef] [Google Scholar]
29. Fridinger S, Szperka C. the cardiovascular impact of intravenous dihydroergotamine for pediatric headache patients. Neurol Rev. 2018;page 6. [Google Scholar]